Oncological Outcomes After Margin‐Negative ( R0 ) Resection in Borderline Resectable Pancreatic Adenocarcinoma: Upfront Surgery Versus Neoadjuvant Treatment—A Contemporary Review
- 9 March 2026
- journal article
- review article
- Published by Wiley in Anz Journal of Surgery
Abstract
Background: Achieving a margin‐negative (R0) resection in borderline resectable pancreatic cancer (BRPC) is a critical prognostic determinant. The optimal clinical strategy—neoadjuvant therapy (NAT) versus upfront surgery (UFS)—remains a key clinical question. Methods: This narrative review synthesized contemporary evidence from studies published between 2009 and 2025, encompassing a total of 5598 patients with BRPC. The analysis compared oncological outcomes between NAT and UFS, specifically focusing on resection rates, R0 resection frequency, and median overall survival (OS). Mixed‐cohort studies lacking BRPC subgroup analysis were excluded. Results: Evidence from both comparative and single‐arm studies indicated that the majority of cohorts achieved significantly higher R0 resection rates and improved median OS following NAT. Resection rates after NAT ranged from 29% to 90%, whereas UFS cohorts reported rates between 62% and 92%. Although resection was more frequent in UFS groups, NAT cohorts demonstrated superior oncological margins; R0 rates in NAT groups ranged from 23% to 100% compared to 14% to 90% in UFS groups. This translated into a survival benefit, with NAT groups achieving a median OS of 11.0 to 43.9 months versus 11.6 to 27.8 months for UFS. NAT also facilitated superior pathological downstaging and reduced lymph node positivity. Conclusion: Neoadjuvant therapy, utilizing potent multi‐agent regimens, significantly improves R0 resection rates and overall survival in BRPC and is increasingly recognized as the preferred clinical strategy. Currently, this survival benefit is not clearly established for patients with upfront resectable disease.Keywords
This publication has 79 references indexed in Scilit:
- Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: Intention‐to‐treat analysis compared with upfront surgeryJournal of Hepato-Biliary-Pancreatic Sciences, 2020
- Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant ChemotherapyJAMA Surgery, 2019
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic AdenocarcinomaJAMA Oncology, 2018
- Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancerBritish Journal of Surgery, 2018
- Neoadjuvant therapy in pancreatic cancer: a systematic review and meta‐analysis of prospective studiesCancer Medicine, 2017
- A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvementCancer Chemotherapy and Pharmacology, 2017
- Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contactCancer Chemotherapy and Pharmacology, 2016
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic CancerJAMA Surgery, 2016
- Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumorsSurgery Today, 2016
- Neoadjuvant GTX Chemotherapy and IMRT‐based chemoradiation for borderline resectable pancreatic cancerJournal of Surgical Oncology, 2011